Corporate Presentation

Corporate Presentation - March 2024

Download Presentation

Email Alerts

Register to receive real time alerts

Sign Up

IR Contacts

Get in touch with our IR team

Contact Us

Latest Press Releases
Apr 9, 2024

Professor Jacky Smith will present on the reduction of cough bouts with nalbuphine ER observed in patients with IPF in the CANAL trial NEW HAVEN, Conn., April 9, 2024 /PRNewswire/ -- Trevi...

Apr 4, 2024

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in...

Apr 2, 2024

Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a...

View All Press Releases

Monday, April 8, 2024
1:30pm - 2:10pm EDT

View All Events

We are developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and prurigo nodularis. Haduvio has a unique mechanism of action that targets cough centrally and peripherally and has the potential for a synergistic anti-tussive effect to treat chronic cough.

Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of chronic cough patients who currently have few treatment options.

Explore Our Pipeline